Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), has appointed Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The move follows the company's decision to combine the COO roles for Drug Substances and Drug Products into a single position, aligning with Siegfried's strategy to provide integrated end-to-end solutions across the pharmaceutical value chain.
Montanha brings over 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of approximately 30 manufacturing sites across multiple regions. His career includes senior leadership roles at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
According to the press release, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. His appointment reflects the company's commitment to enhancing its capabilities as a CDMO, particularly in offering seamless services from drug substances to drug products. For HR vendors, this signals a growing demand for integrated talent management solutions that support operational excellence and cross-functional leadership in the pharmaceutical supply chain.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, said: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He has lived and worked across Europe and Latin America, giving him a broad international perspective.
The appointment is strategic for Siegfried as it seeks to streamline operations and offer integrated solutions. The company, with 16 sites globally, reported sales of CHF 1,327.8 million in 2025 and employs over 3,800 people. Its stock is listed on the SIX Swiss Exchange under the ticker SFZN. For more information, visit www.siegfried.ch.
This leadership change signals Siegfried's focus on operational excellence and integration, which are critical for CDMOs competing in a market where pharmaceutical companies increasingly seek partners capable of handling complex manufacturing from development to commercial production. For vendors serving the HR industry, this trend underscores the importance of providing tools that support global talent acquisition, leadership development, and operational efficiency in highly regulated environments.
